| 20.56 -0.9 (-4.19%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.69 | 1-year : | 30.01 |
| Resists | First : | 22 | Second : | 25.69 |
| Pivot price | 20.72  |
|||
| Supports | First : | 19.39 | Second : | 17.79 |
| MAs | MA(5) : | 20.8 |
MA(20) : | 20.25 |
| MA(100) : | 18.8 |
MA(250) : | 22.29 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 81.9 |
D(3) : | 77.6 |
| RSI | RSI(14): 51.6 |
|||
| 52-week | High : | 61.06 | Low : | 13.69 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TECX ] has closed above bottom band by 45.3%. Bollinger Bands are 35.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 21.81 - 21.96 | 21.96 - 22.08 |
| Low: | 18.75 - 18.88 | 18.88 - 18.99 |
| Close: | 20.36 - 20.58 | 20.58 - 20.77 |
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Thu, 01 Jan 2026
Analysts Are Bullish on Top Healthcare Stocks: Tectonic Therapeutic (TECX), Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Wed, 10 Dec 2025
Tectonic Therapeutic (TECX): LifeSci Capital Reiterates Buy Rating - Insider Monkey
Sat, 22 Nov 2025
Tectonic Therapeutic (NASDAQ:TECX) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Mon, 17 Nov 2025
Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point (TECX) - Seeking Alpha
Thu, 06 Nov 2025
Tectonic Therapeutic Reports Q3 2025 Financial Results - TipRanks
Thu, 30 Oct 2025
Tectonic Therapeutics stock maintains Outperform rating at Oppenheimer - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 38.3 (%) |
| Held by Institutions | 65.1 (%) |
| Shares Short | 5,350 (K) |
| Shares Short P.Month | 5,000 (K) |
| EPS | -2.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -21.5 % |
| Return on Equity (ttm) | -32.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -62 (M) |
| Levered Free Cash Flow | -46 (M) |
| PE Ratio | -7.65 |
| PEG Ratio | 0 |
| Price to Book value | 1.43 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|